Indications and uses
For use as a protectant against further irritation or to relieve dryness of the eye.
For use as a protectant against further irritation or to relieve dryness of the eye.
Instill 1 or 2 drops in the affected eye(s) as needed.
Store at room temperature.
| Active Ingredients | Purpose |
| Dextran 70 0.1% | Lubricant |
| Hypromellose 2910 0.3% | Lubricant |
For external use only
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Store at room temperature.
Calcium chloride, magnesium chloride, potassium chloride, purified water, sodium bicarbonate, sodium chloride, zinc chloride, hydrochloric acid and/or sodium hydroxide and/or carbon dioxide to adjust pH.
In the U.S. call 1-800-757-9195
www.tearsnaturale.com
Severe Dry Eye
Preservative-Free
BION®
TEARS
LUBRICANT EYE DROPS
28 Single-Use Vials
0.4 ml (0.015 FL OZ) Each
STERILE
Alcon
DIRECTIONS (HOW TO USE)
Make sure container is intact before use.
To open, COMPLETELY
TWIST OFF TAB.
Do not pull off.
Instill 1 or 2 drops in the
affected eye(s) as needed.
Throw away container.
Do not reuse.
Once opened, discard.
All four containers within a
pouch must be used within four
days of opening the pouch.
Tamper Evident: Containers are sealed in a protective foil pouch.
Use only if foil pouch is
undamaged at time of purchase.
BION® TEARS Lubricant Eye Drops is an
advanced tear substitute especially formulated
and packaged
for persistent dry eye conditions
requiring frequent therapy.
MONEY BACK GUARANTEED
To fully assess comfort, a 3 to 4-week trial of
BION® TEARS is recommended when switching
from another brand of lubricant eye drops.
If, however, you are not satisfied with the comfort
BION® TEARS provides, we ask that you send the
unused portion of the product and the sales
receipt, with a brief description of why you
were dissatisfied, to QA/Consumer Affairs,
Alcon Laboratories, Fort Worth, TX 76134-2099.
You will receive a full refund within 6 to 8 weeks.
U.S. Patent no. 5,403,598
© 2003, 2005, 2006, 2009, 2021 Alcon, Inc.
Manufactured for:
Alcon
Alcon Laboratories, Inc.
Fort Worth, TX 76134-0109
Made in France
419199
Lot:
Exp.:

| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1088217 | BION TEARS 0.1 % / 0.3 % Ophthalmic Solution | PSN | 11 |
| 309714 | dextran 70 0.1 % / hypromellose 0.3 % Ophthalmic Solution | PSN | 11 |
| 1088217 | dextran 70 1 MG/ML / hypromellose 3 MG/ML Ophthalmic Solution [Bion Tears] | SBD | 11 |
| 309714 | dextran 70 1 MG/ML / hypromellose 3 MG/ML Ophthalmic Solution | SCD | 11 |
| 1088217 | Bion Tears (dextran 70 0.1 % / hypromellose 0.3 % ) Ophthalmic Solution | SY | 11 |
| 309714 | dextran 70 0.1 % / hypromellose 0.3 % Ophthalmic Drops | SY | 11 |
| Class | Version | Type | Effective |
|---|---|---|---|
| DEXTRAN 70 Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0065-0419-18 | BION TEARS | 28 in 1 CARTON | SOLUTION/ DROPS | 28 | 11 | |
| 0065-0419-18 | BION TEARS | 0.4 mL in 1 VIAL | SOLUTION/ DROPS | 0.4 | 11 | |
| 0065-0419-28 | BION TEARS | 0.4 mL in 1 VIAL | SOLUTION/ DROPS | 0.4 | 11 | |
| 0065-0419-28 | BION TEARS | 28 in 1 CARTON | SOLUTION/ DROPS | 28 | 11 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0065-0419-18 | EA - Each | 0065-0419 | 57facf56-1432-4487-bb2f-0ac24729ebda | 1 | 2016-07-19 |
| 0065-0419-28 | EA - Each | 0065-0419 | 647b105c-1411-4cdf-9d10-e29d8e12941b | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Dextran 70 | ACTIVE INGREDIENT | 7SA290YK68 | 1 | |
| Hypromellose 2910 (4000 Mpa.s) | ACTIVE INGREDIENT | RN3152OP35 | 1 | |
| Dextran 70 | ACTIVE MOIETY | 7SA290YK68 | 1 | |
| Hypromelloses | ACTIVE MOIETY | 3NXW29V3WO | 1 | |
| Calcium Chloride | INACTIVE INGREDIENT | M4I0D6VV5M | 1 | |
| Carbon Dioxide | INACTIVE INGREDIENT | 142M471B3J | 1 | |
| Hydrochloric Acid | INACTIVE INGREDIENT | QTT17582CB | 1 | |
| Magnesium Chloride | INACTIVE INGREDIENT | 02F3473H9O | 1 | |
| Potassium Chloride | INACTIVE INGREDIENT | 660YQ98I10 | 1 | |
| Sodium Bicarbonate | INACTIVE INGREDIENT | 8MDF5V39QO | 1 | |
| Sodium Chloride | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| Zinc Chloride | INACTIVE INGREDIENT | 86Q357L16B | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0065-0419 | 0065-0419-28, 0065-0419-18 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Dextran 70 | 7SA290YK68 | ACTIB |
| Hypromellose 2910 (4000 Mpa.s) | RN3152OP35 | ACTIB |
| Calcium Chloride | M4I0D6VV5M | IACT |
| Magnesium Chloride | 02F3473H9O | IACT |
| Potassium Chloride | 660YQ98I10 | IACT |
| Water | 059QF0KO0R | IACT |
| Sodium Bicarbonate | 8MDF5V39QO | IACT |
| Sodium Chloride | 451W47IQ8X | IACT |
| Zinc Chloride | 86Q357L16B | IACT |
| Hydrochloric Acid | QTT17582CB | IACT |
| Sodium Hydroxide | 55X04QC32I | IACT |
| Carbon Dioxide | 142M471B3J | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / ORAL | 1300 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GRANULE, EFFERVESCENT / ORAL | 267 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING / ORAL | 107 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, SOLUTION / INTRAVENOUS | 52 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EFFERVESCENT / ORAL | 57600 mg | ||
| Magnesium Chloride | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION/ DROPS / OPHTHALMIC | 0.03 %w/v | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 6 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / BUCCAL | 42 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / OPHTHALMIC | 55 mg | ||
| Zinc Chloride | ZINC CHLORIDE | 86Q357L16B | SOLUTION/ DROPS / OPHTHALMIC | NA | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | LOZENGE / ORAL | 100 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING / ORAL | 107 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EXTENDED RELEASE / ORAL | 81 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / ORAL | 360 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GRANULE, EFFERVESCENT / ORAL | 267 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg | ||
| Calcium Chloride | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION/ DROPS / OPHTHALMIC | 0.02 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / ORAL | ADJ PH | ||
| Potassium Chloride | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION/ DROPS / OPHTHALMIC | 0.14 %w/v | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| Carbon Dioxide | CARBON DIOXIDE | 142M471B3J | INJECTION / INTRAVENOUS | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / OPHTHALMIC | 55 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 160 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRAVITREAL | 0.18 %w/v | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / RESPIRATORY (INHALATION) | 2 %w/w | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 3059 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRAMUSCULAR | 175 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | POWDER, FOR SOLUTION / ORAL | 1250 mg/100ml | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 160 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 4 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 3219 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, FILM COATED / ORAL | 86 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, SOLUTION / INTRAVENOUS | 52 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRATHECAL | 0.05 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING / ORAL | 107 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, COATED / ORAL | 10.6 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | LOZENGE / ORAL | 100 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EXTENDED RELEASE / ORAL | 81 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRAVENOUS | 812 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GRANULE, EFFERVESCENT / ORAL | 267 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 3059 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRAMUSCULAR | 175 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | POWDER, FOR SOLUTION / ORAL | 1250 mg/100ml | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / ORAL | ADJ PH | ||
| Carbon Dioxide | CARBON DIOXIDE | 142M471B3J | INJECTION / INTRAVENOUS | ADJ PH | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, CHEWABLE / ORAL | 140 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / BUCCAL | 240 mg | ||
| Sodium Bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 160 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BION TEARS | DEXTRAN, HYPROMELLOSE | Alcon Laboratories, Inc. | e48d82f0-2f18-e514-4caa-e397d6713b99 | 2023-12-14 | Warnings | 0065-0419-28 0065-0419-18 0065-0419 00065041918 00065041928 34aa9128-4bc4-45a6-aeae-a8c1f7699183 e48d82f0-2f18-e514-4caa-e397d6713b99 |
Adverse event summaries are temporarily unavailable. Other product information remains available.